Riskpilot← Back to searchSign inGet full accessNORWEGIAN PHARMA AS
ASActiveOrg 893844422Mosaberget 11, 4331 ÅlgårdWholesale of other food · NACE 4638Est. 20092 employeeswww.norwegianpharma.com
Revenue 2024
NOK 11M
+9% vs 2023
EBITDA margin
13.9%
0% vs 2023
Equity ratio
75.5%
Financial strength
Net profit 2024
NOK 1,3M
+1% vs 2023
| Revenue | NOK 11M | +9% |
| EBITDA | NOK 1,5M | +0% |
| Net profit | NOK 1,3M | +1% |
| Total assets | NOK 4,4M | -27% |
| Equity | NOK 3,3M | -23% |
| Employees | 2 | — |
Legal name
NORWEGIAN PHARMA AS
Org number
893844422
Legal form
Aksjeselskap
NACE code
4638 · Wholesale of other food
Founded
10. mars 2009
Share capital
NOK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Drive handel med naturprodukter, herunder eksport av samme, samt hva hermed står i naturlig forbindelse. Selskapet kan også opptre som interessent i andre foretagender, ved aksjetegning eller på annen måte.
Address
Mosaberget 11, 4331 Ålgård
Website
www.norwegianpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 15 872 | 11 396 | 10 862 | 10 039 | 10 961 |
| Staff expenses | −1 231 | −1 225 | −1 248 | −1 289 | −1 251 |
| EBITDA | 4 804 | 2 359 | 2 022 | 1 522 | 1 529 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 4 804 | 2 359 | 2 022 | 1 522 | 1 529 |
| Net financials | 57 | 10 | −0 | 68 | 82 |
| Profit before tax | 4 862 | 2 368 | 2 022 | 1 590 | 1 610 |
| Tax | 1 073 | 524 | 448 | 353 | 358 |
| Net profit | 3 788 | 1 845 | 1 574 | 1 237 | 1 252 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 13 377 | 9 056 | 6 880 | 6 012 | 4 385 |
| Equity | 11 652 | 7 496 | 5 070 | 4 307 | 3 309 |
| Long-term debt | 0 | 2 | 0 | 0 | 13 |
| Short-term debt | 1 725 | 1 558 | 1 810 | 1 704 | 1 062 |
| Total debt | 1 725 | 1 560 | 1 810 | 1 704 | 1 076 |
EBITDA margin
13.9%
This company
15.8%
Market median
-12% vs market
20202024
Equity ratio
75.5%
This company
38.2%
Market median
+98% vs market
20202024
Return on equity
37.8%
This company
18.4%
Market median
+105% vs market
20202024
Net profit margin
11.4%
This company
8.1%
Market median
+41% vs market
20202024
Asset turnover
2.50×
This company
1.12×
Market median
+123% vs market
20202024
Debt / equity
0.32×
This company
0.62×
Market median
+48% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2017 | |
| Board of Directors | 2017 | |
| Board of Directors | 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 20% | 20% | 2024 | |
| Company | 20% | 20% | 2024 | |
| Individual | 20% | 20% | 2024 | |
| Company | 20% | 20% | 2024 | |
| Company | 20% | 20% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORWEGIAN PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pål Michael Smith | Board of Directors | 0 companies |
| Stig Nordsveen | Board of Directors | 0 companies |
| Ole Fredrik Haven | Board of Directors | 0 companies |